ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?-Reference-Cited by-同舟云学术

ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?

Published:2002-11 Issue:6 Volume:4 Page:420-440
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:

Author:

Bakris George L.,Weir Matthew

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1524-6175.2002.01641.x/fullpdf

Reference19 articles.

1. 1 US Renal Data System. USRDS 1999 Annual Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.

2. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group;Lewis;N Engl J Med,1993

3. Preventing end-stage renal disease;Mogensen;Diabetes Med,1998

4. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group;Laffel;Am J Med,1995

5. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study;Ravid;Arch Intern Med,1996

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An updated review on diabetes mellitus: Exploring its etiology, pathophysiology, complications and treatment approach;IP International Journal of Comprehensive and Advanced Pharmacology;2024-03-15

2. Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review;Frontiers in Pharmacology;2023-02-13

3. Applying National Diabetic Care Standards for the Management of a Hispanic Population Attending a Free Clinic;Journal of Community Health;2023-02-08

4. SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease;Diabetes and Cardiovascular Disease;2023

5. Diabetes and Hypertension;Diabetes and Cardiovascular Disease;2023